3 Indian-origin charged in US with visa fraud

Agencies
April 2, 2019

Washington, Apr 2: Three Indian-origin consultants have been charged in the US with visa fraud for allegedly submitting sham applications for H-1B visas to gain a competitive advantage over competing firms.

A federal grand jury last month indicted Kishore Dattapuram, of Santa Clara, Kumar Aswapathi, of Austin, Texas, and Santosh Giri, of San Jose, on 10 counts of substantive visa fraud and one count of conspiracy to commit visa fraud, the Justice Department said in a statement.

The H-1B visa programme allows foreign workers to obtain temporary authorisation to live and work for employers in the United States.

In order to secure an H-1B visa, an employer or other sponsor must submit an 'I-129' petition to the United States Citizenship and Immigration Services.

A petition and associated documentation must confirm the existence and duration of the job waiting for the worker, and describe key details including the wages associated with the position.

According to the eight-page indictment, Dattapuram, 49, Aswapathi, 49, and Giri, 42 operated Nanosemantics, Inc, a Santa Clara-based consulting firm whose services included placing skilled foreign workers at software and technology companies in the Bay Area. They worked together to submit fraudulent H-1B visa applications on behalf of foreign workers in order to gain a competitive advantage over competing firms.

The defendants allegedly used Nanosemantics to submit fraudulent I-129 petitions and obtain H-1B visas for workers that the defendants could later place at local companies.

By maintaining a group of available workers, the defendants would gain a competitive advantage over consultants that properly applied for paperwork only after matching a qualified worker to and available job.

According to the indictment, several of the I-129 petitions submitted by defendants stated that particular workers had specific jobs waiting for them at designated companies when, in reality, the defendants knew that these jobs did not exist.

Further, the defendants allegedly sought the cooperation of third parties to conceal their fraud.

For example, defendants allegedly orchestrated payments by Nanosemantics to at least one individual for permission to list his company as the employer for foreign workers even though Nanosemantics actually intended to place the workers elsewhere.

Further, defendants allegedly coached foreign workers and others, to respond to government inquiries in a way that would prevent the government from discovering the fraud.

The defendants were charged with one count of conspiracy to commit visa fraud and ten counts of substantive visa fraud.

The defendants were arrested last week in their respective towns of residence.

All three defendants entered pleas of not guilty and were released on bonds. They are next scheduled to appear on May 13, 2019, for a status conference before Judge Edward J Davila, US District Judge.

If convicted, the defendants face a maximum sentence of ten years, and a fine of USD 250,000, plus restitution if appropriate for each violation.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 18,2020

Washington, May 18: US President Donald Trump on Sunday called his predecessor Barak Obama a ‘grossly incompetent president’.

The Trump’s reaction came after Obama on Saturday criticised the US authorities' response to the coronavirus outbreak.

“He (Obama) was an incompetent president. That’s all I can say. Grossly incompetent,” Trump told reporters at the White House on his arrival from Camp David.

Trump was responding to a question on the virtual commencement address by Obama a day earlier.

In his address to college graduates, Obama had said that the COVID-19 pandemic has exposed the American leadership.

“More than anything, this pandemic has fully, finally torn back the curtain on the idea that so many of the folks in charge know what they’re doing,” Obama said without naming officials.

“A lot of them aren’t even pretending to be in charge,” he added.

There was no immediate response from the office of the former president on the remarks made by Trump.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 10,2020

Dubai, Jan 10: Iran denied on Thursday that a Ukrainian airliner that crashed near Tehran had been hit by a missile, Iranian government spokesman Ali Rabiei said in a statement, according to state TV.

"All these reports are a psychological warfare against Iran. All those countries whose citizens were aboard the plane can send representatives and we urge Boeing to send its representative to join the process of investigating the black box".

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.